Videos

PowerVision Shows `True Accommodation’

By Jackie Wengrod | May 17, 2016

PowerVision has developed a fluid-controlled accommodating intraocular lens (IOL), the FluidVision AIOL, as the first platform to provide “true accommodation” by mimicking the eye’s natural…

Read More

Glaukos Recounts IPO Roadshow

By Jackie Wengrod | May 17, 2016

Glaukos completed its IPO on June 25, 2015, but the road getting there was a long one. Before going public, the company that was founded…

Read More

InnFocus’ Trenary Discusses New Funding, Timeline

By Jackie Wengrod | May 17, 2016

To watch InnFocus’ OIS Companies to Watch Presentaion Click Here InnFocus CEO Russ Trenary participated in our Glaucoma section of OIS@ASCRS. We caught up with…

Read More

Lindstrom Eyes Improvements to Eye Drops

By Jackie Wengrod | May 16, 2016

Richard Lindstrom, MD, led the OIS@ASRCS breakfast breakout session “Innovative Alternatives to Drops.” Hear his recap of the problem and the potential solutions that may…

Read More

Masters of The Universe

By Jackie Wengrod | May 13, 2016

The day concluded with the Masters of the Universe panel where AcuFocus executive chairman Jim Mazzo led a discussion between Link and executives from Abbott…

Read More
The “Post-Game Wrap-Up” with OIS@ASCRS Co-Chairs - OIS@ASCRS 2016

The “Post-Game Wrap-Up” with OIS@ASCRS Co-Chairs

By Jackie Wengrod | May 13, 2016

OIS co-chairs and VCs Emmett Cunningham, MD, Gil Kliman, MD, and Bill Link, PhD, sit down with OISTV to review the highlights of the May…

Read More
Aerie’s CEO Says FDA, Investors Helped Get Company Back on Track

Aerie’s CEO Says FDA, Investors Helped Get Company Back on Track

By Jackie Wengrod | February 3, 2016

Aerie Pharmaceuticals Inc. didn’t quite enjoy the “roller coaster ride” that followed the disap-pointing results of Rocket 1, a trial testing Rhopressa, a potential treatment…

Read More

LacriPen Writing Exciting Script for Founders

By Jackie Wengrod | December 1, 2015

Interview

Read More

Opthea Taking New Approach to Combat Wet AMD

By Jackie Wengrod | December 1, 2015

Megan Baldwin, PhD, Managing Director and CEO of Opthea, gives an update on OPT-302, a soluble receptor consisting of the first three extracellular domains of…

Read More

Ocular Therapeutix Taking Aim at Allergy Market

By Jackie Wengrod | November 30, 2015

Amar Sawhney, PhD, Chairman, Chairman, President & CEO of Ocular Therapeutics, touts the performance of Dextenza, the company’s anti-allergy medication. Instead of taking one drop…

Read More

`Mythbuster’ Cheskin on Powervision’s Future Pipeline, Strength of IOLs

By Jackie Wengrod | November 30, 2015

Barry Cheskin, co-founder, president, and CEO of PowerVision, introduces the company’s next iteration, Fluidvision 2020, a new IOL that doubles the power of accommodation for…

Read More

Novaliq Goes After Dry Eye Disease

By Jackie Wengrod | November 30, 2015

Bernhard Gunther, CEO of Novaliq GmbH, delivers an update on the progress of his compay’s drug delivery pipeline. Novaliq develops innovative pharmaceutical formulations based on…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.